Pipeline



pipelinefeb09.jpg

Intercytex has four products in development:

 

  • VAVELTA®, a skin repair and rejuvenation product intended to improve the feel, function and appearance of skin damaged by scarring and the aging process  

  • SHEF-1, development of a stem cell line suitable for differentiation into retinal pigment epithelial (RPE) cells, being carried out in collaboration with the London Project to Cure Blindness

  • ICX-SKN, being developed as a skin graft replacement for burns and acute wounds, Phase I trials completed
  • ICX-TRC, a hair regeneration product, in Phase II trials.


All Intercytex' products are derived from unmodified human cells.

Intercytex has a broad patent base protecting its product portfolio. This comprises both inventions generated in-house and those in-licensed or acquired from third parties.